Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy

By afschroeder • November 5, 2026

Zimmerman MP, Huang AY, Cox EK, Al Abosy R, Chong WL, Bastian AG, Vietor K, Choutri YA, Collier JL, Zhabotynsky V, Wang H, Fung M, Maruvada S, Onuoha PC, Weiss SA, Robitschek EJ, Lin JR, Vallius T, Pant SM, Sorger PK, Hugo W, Sen DR, Haining WN, Sharpe AH, Miller BC. Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy. J Immunother Cancer. 2026 Nov 4;14(11):e015096. doi: 10.1136/jitc-2026-015096. PMID: 42982509.

Tags: Dermatology, immune checkpoint inhibitor, Major histocompatibility complex - MHC, monocyte, Publications, T-lymphocytes

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study

Paller AS, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H,[...]

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Gold LS, Armstrong AW, Vender RB, Soung J, Pink AE, Cafone J, Edem BE, Reyes-Servin O, Jiang J, Cresswell K, DeKlotz CMC, Miller-Kassamali M, Yang[...]

Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities

Stein Gold L, Sofen HL, Siu K, Syeed S, Edson-Heredia E, Mitchell B, Goddard E, Kranz B, Gillespie-Akar L, Armstrong AW. Real-World Patient and Disease[...]